Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma

NCT03077698 is registered in ClinicalTrials.gov with Xenetic Biosciences, Inc. as lead sponsor.

NCT NCT03077698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03077698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Lead sponsor
Xenetic Biosciences, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 14, 2017
Completion date
July 17, 2020
Enrollment
25 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer